BeiGene, Ltd. is a biotechnology company that develops and commercializes innovative cancer treatments. The company was founded in 2010 and is headquartered in George Town, Grand Cayman. BeiGene's portfolio includes several drug candidates that target cancer cells and the tumor microenvironment. The company's lead product, Brukinsa, is a treatment for mantle cell lymphoma that has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). BeiGene also has partnerships with several pharmaceutical companies, including Amgen, Merck, and Novartis.